CN116261447A - 局部治疗白癜风 - Google Patents

局部治疗白癜风 Download PDF

Info

Publication number
CN116261447A
CN116261447A CN202180072662.8A CN202180072662A CN116261447A CN 116261447 A CN116261447 A CN 116261447A CN 202180072662 A CN202180072662 A CN 202180072662A CN 116261447 A CN116261447 A CN 116261447A
Authority
CN
China
Prior art keywords
week
vitiligo
patient
ruxolitinib
cream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180072662.8A
Other languages
English (en)
Chinese (zh)
Inventor
K·巴特勒
J·李
孙慷
F·郭
M·豪威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/023,269 external-priority patent/US20210030672A1/en
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CN116261447A publication Critical patent/CN116261447A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202180072662.8A 2020-09-16 2021-09-16 局部治疗白癜风 Pending CN116261447A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/023,269 2020-09-16
US17/023,269 US20210030672A1 (en) 2019-06-10 2020-09-16 Topical treatment of vitiligo by a jak inhibitor
PCT/US2021/071479 WO2022061351A1 (en) 2020-09-16 2021-09-16 Topical treatment of vitiligo

Publications (1)

Publication Number Publication Date
CN116261447A true CN116261447A (zh) 2023-06-13

Family

ID=78135236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180072662.8A Pending CN116261447A (zh) 2020-09-16 2021-09-16 局部治疗白癜风

Country Status (6)

Country Link
US (2) US20230364095A1 (https=)
EP (1) EP4213800A1 (https=)
JP (1) JP2023542137A (https=)
CN (1) CN116261447A (https=)
CA (1) CA3195357A1 (https=)
WO (1) WO2022061351A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939759A (zh) * 2013-12-02 2016-09-14 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
WO2019138291A2 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
US20200069965A1 (en) * 2017-04-26 2020-03-05 Yale University Compositions and Methods for Treating Vitiligo

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
PE20130216A1 (es) * 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
US9642934B2 (en) * 2013-08-09 2017-05-09 Gunze Limited Bone regeneration material kit, paste-like bone regeneration material, bone regeneration material, and bone bonding material
SG11201701292XA (en) * 2014-08-27 2017-03-30 Abbvie Inc Topical formulation
MX2018001831A (es) * 2015-08-14 2018-09-06 Univ Columbia Biomarcadores para el tratamiento de alopecia areata.
US10894837B2 (en) * 2016-12-16 2021-01-19 Université De Bordeaux MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US20210030672A1 (en) * 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
JP7532511B2 (ja) * 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939759A (zh) * 2013-12-02 2016-09-14 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
US20200069965A1 (en) * 2017-04-26 2020-03-05 Yale University Compositions and Methods for Treating Vitiligo
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
WO2019138291A2 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID ROSMARIN等: ""Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial"", 《THE LANCET》, vol. 396, no. 10244, 11 July 2020 (2020-07-11), pages 110 - 120, XP086211925, DOI: 10.1016/S0140-6736(20)30609-7 *

Also Published As

Publication number Publication date
JP2023542137A (ja) 2023-10-05
WO2022061351A1 (en) 2022-03-24
CA3195357A1 (en) 2022-03-24
US20230293431A1 (en) 2023-09-21
US20230364095A1 (en) 2023-11-16
EP4213800A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US11590138B2 (en) Topical treatment of vitiligo by a jak inhibitor
JP2021073258A (ja) トラジピタントによる治療方法
KR20040100844A (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
CN106922128B (zh) 睾酮制剂及其治疗方法
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US11878008B2 (en) Composition for preventing or treating atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20250275974A1 (en) Treatment of frontal fibrosing alopecia
JP2022547478A (ja) アトピー性皮膚炎のかゆみを軽減するためのルキソリチニブ製剤
WO2019113475A1 (en) Topical ointment formulations and their use in treating skin conditions
KR20200068692A (ko) 섬유증 치료용 조성물 및 방법
CN116261447A (zh) 局部治疗白癜风
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
JP2025502098A (ja) うつ病の治療のための組成物及び方法
JP6058156B2 (ja) アトピー性皮膚炎を処置するためのピドチモドの使用
JP2019516798A (ja) 幼少期に適用するためのカルボン酸
WO2025096373A1 (en) Ruxolitinib for use in the treatment of prurigo nodularis
GB2616294A (en) Composition for use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230613

WD01 Invention patent application deemed withdrawn after publication